How timing gaps in MS records change drug results

Credibility

Interest

Share:2 min read

Key Takeaway

Gaps in when patients enter MS registries can make medicines look more or less effective, but smart analysis methods can reduce this error.

What They Found

The study looked at people whose MS was followed from the true start of symptoms and compared that to situations where records started later (left-truncation). When records started later, the benefit of disease-modifying therapies (DMTs) on preventing relapses often looked bigger than it really was, especially if the gap was short (like 1 year). If the delay in starting records was linked to patient or disease features (not random), the results were also biased. Measures of disability (getting worse or better) were less affected by these gaps than relapse rates. Using a statistical method called marginal structural models, plus fixing the analysis to a common start time and adjusting for known patient differences, helped reduce the bias.

Who Should Care and Why

People with MS and their caregivers should care because study results influence which drugs doctors think work best, and that affects treatment choices. If a registry starts tracking people late, it can make a medicine seem stronger at preventing relapses than it truly is — like reading the end of a book and thinking you know the whole story. Doctors and researchers benefit because the paper shows ways to correct for these gaps so decisions are based on fair comparisons. Clinic teams using registry data can use the suggested fixes to give more reliable advice about treatment effects. Patients choosing or continuing a DMT can ask their care team whether the evidence came from data that accounted for these timing gaps.

Important Considerations

The study used data from one large registry and statistical models, which can reduce but not completely remove uncertainty. Some bias depends on how long and why records started late, and not every registry or dataset will behave the same way. This means results should be interpreted with caution, and patients should discuss how strong the evidence is with their doctor.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials MS Progression

Article Topics:

Multiple sclerosiscausal inferencedisease-modifying therapiesleft-truncationmarginal structural modelling

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News